Unknown

Dataset Information

0

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.


ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disorder that results in frequent exacerbations and impacts quality of life. It represents a growing burden of health care cost, both from societal and economic perspectives. Short- and long-acting bronchodilators remain the mainstay of therapy in COPD patients. New fixed-dose combination inhalers with novel pharmacological combinations of long-acting ?2-agonists and muscarinic antagonists and delivered once-daily through a variety of devices are currently being developed and licensed for the treatment of COPD. There is mounting research suggesting that combining a fixed dose of a ?2-agonist and a muscarinic antagonist achieves better bronchodilation and clinical outcomes compared with either agent alone. These once-daily dosing inhalers are anticipated to impact favorably on patient preference and compliance. This review examines the fixed-dose combination of tiotropium bromide and olodaterol delivered by a Respimat(®) Soft Mist™ inhaler at doses of 2.5/5 ?g and 5/5 ?g in moderate-to-very-severe COPD, and its potential role in COPD compared with other long-acting ?2-agonist with long-acting muscarinic antagonist combinations and delivery devices.

SUBMITTER: Muruganandan S 

PROVIDER: S-EPMC4476436 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.

Muruganandan Sanjeevan S   Jayaram Lata L  

International journal of chronic obstructive pulmonary disease 20150618


Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disorder that results in frequent exacerbations and impacts quality of life. It represents a growing burden of health care cost, both from societal and economic perspectives. Short- and long-acting bronchodilators remain the mainstay of therapy in COPD patients. New fixed-dose combination inhalers with novel pharmacological combinations of long-acting β2-agonists and muscarinic antagonists and delivered once-daily throug  ...[more]

Similar Datasets

| S-EPMC4391658 | biostudies-literature
| S-EPMC6824359 | biostudies-literature
| S-EPMC8340281 | biostudies-literature
| S-EPMC10259581 | biostudies-literature
| S-EPMC8212527 | biostudies-literature
| S-EPMC6049061 | biostudies-literature
| S-EPMC6437647 | biostudies-literature
| S-EPMC4912717 | biostudies-literature
| S-EPMC5898947 | biostudies-literature
| S-EPMC5702233 | biostudies-literature